Baltimore biotech backed by more than $300M in funding names new CEO
The company hopes to provide a cheaper alternative to the standard screening for lung cancer. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 5, 2024 Category: Pharmaceuticals Authors: Matt Hooke Source Type: news
Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung Cancer Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung Cancer
Narjust Florez, MD, reflects on the significant changes in the treatment landscape of early-stage non-small cell lung cancer in recent years.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Lung Cancer CT Screening Can Save Lives, But Study Finds Downsides
WEDNESDAY, Jan. 3, 2024 -- Numerous studies have confirmed that annual lung cancer screening using CT scans does save lives. However, new data has emerged showing that scans often pick up abnormalities that lead to follow-up invasive tests -- and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2024 Category: General Medicine Source Type: news
Study IDs Downstream Procedure, Complication Rates After Lung Cancer Screening
TUESDAY, Jan. 2, 2024 -- For individuals undergoing low-dose computed tomography (LDCT) scans for lung cancer screening (LCS), the rates of downstream procedures and complications are higher than observed in the National Lung Screening Trial (NLST),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2024 Category: Pharmaceuticals Source Type: news
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 -- (Healthcare Sales & Marketing Network) -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune ... Biopharmaceuticals, Oncology, Licensing Allorion Therapeutics, EGFR, non-small cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 2, 2024 Category: Pharmaceuticals Source Type: news
Ketamine might have power to kill cancer
An international team of researchers exposed brain and lung cancer cells in labs to the illegal party drug. Results showed that the drug stopped the cells from growing and dividing, leading to their death. (Source: the Mail online | Health)
Source: the Mail online | Health - January 1, 2024 Category: Consumer Health News Source Type: news
Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient Death
Iovance Biotherapeutics stock was tumbling Wednesday after the Food and Drug Administration placed a clinical hold on a cancer treatment study following the death of a study patient. (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2023 Category: Consumer Health News Source Type: news
FDA Wants Another Amgen Study on Lumakras
Amgen will need to run another confirmatory study to win full FDA approval of its lung-cancer drug Lumakras. Amgen says the FDA, which granted conditional approval to the drug in 2021, has turned away its application seeking full approval and called on the company to complete the additional study…#amgen #fda (Source: Reuters: Health)
Source: Reuters: Health - December 26, 2023 Category: Consumer Health News Source Type: news
Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)
FDA Has Issued New Postmarketing Requirement
LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval
THOUSAND OAKS, Calif., Dec. 26, 2023 -- (Healthcare Sales & Marketing Network) -- Amgen ... Biopharmaceuticals, Oncology, FDA Amgen, LUMAKRAS, sotorasib, non-small cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 26, 2023 Category: Pharmaceuticals Source Type: news
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with advanced EGFR-mutated non-small cell lung cancer previously treated with two or more systemic... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 22, 2023 Category: Drugs & Pharmacology Source Type: news
Kate Micucci Is Cancer-Free After Lung Surgery Earlier This Month: “I’m Excited to Hang With My Little Boy for Christmas”
Kate Micucci says she’s cancer-free after undergoing surgery last week to treat a lung cancer diagnosis. The Raising Hope and Big Bang Theory actress shared the news over the weekend on TikTok, where she confirmed that the surgery “went great” and the results “came back that it worked.” “I don’t…#katemicucci #tiktok #sicktok #frostedflakes #goodmorningamerica (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2023 Category: Consumer Health News Source Type: news
Coming to Terms With My Diagnosis
It can be overwhelming to be diagnosed with metastatic small-cell lung cancer. Here, three survivors share their stories. (Source: WebMD Health)
Source: WebMD Health - December 19, 2023 Category: Consumer Health News Source Type: news
Dignitas’s tough rules on who they will help to die as Esther Rantzen signs up
Dame Esther Rantzen has joined assisted dying clinic Dignitas after battling lung cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - December 19, 2023 Category: Consumer Health News Source Type: news
Esther Rantzen says she's joined assisted dying clinic
The broadcaster tells the BBC she will consider assisted dying if her lung cancer treatment fails. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 19, 2023 Category: Consumer Health News Source Type: news
AI predicts cardiovascular disease mortality risk on chest CT
A deep-learning algorithm could predict a patient’s risk of atherosclerotic cardiovascular disease (ASCVD) from analysis of noncontrast-enhanced chest CT exams, according to a study presented at the recent RSNA meeting. Researchers, led by presenter Vineet Kalathur Raghu, PhD, from Harvard Medical School and Massachusetts General Hospital, trained an AI model to predict a patient’s probability of cardiovascular mortality within 12 years. In testing, the algorithm yielded a statistically significant improvement in prediction performance over a baseline regression model. The algorithm, called CT-CV-Risk, also predicte...
Source: AuntMinnie.com Headlines - December 19, 2023 Category: Radiology Authors: Erik L. Ridley Tags: CT Artificial Intelligence Image Processing Chest Radiology Source Type: news
